Integrative Proteomic and Transcriptomic Analysis Provides Evidence for TrkB (NTRK2) as a Therapeutic Target in Combination With Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer

Oncotarget - United States
doi 10.18632/oncotarget.24361

Related search